-
Article
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) a...
-
Article
Open AccessLow expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways
Rhabdomyosarcoma (RMS) is the most frequent form of pediatric soft-tissue sarcoma. It is divided into two main subtypes: ERMS (embryonal) and ARMS (alveolar). Current treatments are based on chemotherapy, surg...
-
Article
Open AccessLong-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences...
-
Article
L’organisation française en réseau de soins pour la prise en charge des sarcomes
Les sarcomes sont des cancers rares et hétérogènes, dont la prise en charge est complexe et non optimale pour la majorité des patients. Les trois éléments clés de la prise en charge sont l’obtention d’un diagn...
-
Article
Open AccessEfficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe...
-
Article
Prostate cancer screening: contrasting trends
Our previously published data showed rapidly increasing rates of prostate cancer screening in men aged 50–74, which rose from 36 % in 2005 to 48 % in 2008. Based on men’s reported intentions at that time, thi...
-
Article
Open AccessA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells.
-
Article
Open AccessTrabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS).
-
Article
Open AccessA phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
Soft tissue sarcomas (STS) are rare tumours for which treatment options are limited in the advanced setting. Histone deacetylase inhibitors have shown activity in preclinical models of STS.
-
Article
Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs
Gastrointestinal stromal tumors (GISTs) are the most common human sarcoma. Most of the data available on GISTs derive from retrospective studies of patients referred to oncology centers. The MolecGIST study so...
-
Article
Open AccessCytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor rec...
-
Article
Open AccessPerformance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma
We investigated prognostic factors (PFs) for 90-day mortality in a large cohort of advanced/metastatic soft tissue sarcoma (STS) patients treated with first-line chemotherapy.
-
Chapter
Tumeurs stromales gastro-intestinales
Les tumeurs stromales gastro-intestinales (Gastrointestinal Stromal Tumors ou GIST en anglais) sont des tumeurs malignes rares du tube digestif. Leur origine présumée est la cellule de Cajal qui assure la contrac...
-
Article
Open AccessIdentification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF). The precise target of imatinib in AF and predictive factors for response to treatment are unk...
-
Article
Open AccessA prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
Preliminary data indicate that the molecular epidemiology of localised gastrointestinal stromal tumour (GIST) may be different from that of advanced GIST. We sought to investigate the molecular epidemiology of...
-
Article
Open AccessHigh frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
Fibromatosis comprises distinct clinical entities, including sporadic extra-abdominal fibromatosis, which have a high tendency for recurrence, even after adequate resection. There are no known molecular biomar...
-
Chapter
Tumeurs stromales gastro-intestinales (GIST)
Les tumeurs stromales gastro-intestinales (GIST) n’étaient pas reconnues comme des entités cliniques distinctes en 1998, bien que plusieurs équipes d’anatomopathologistes aient rapporté d...
-
Chapter
Gastrointestinal stromal tumours
Gastrointestinal stromal tumours (GIST) are rare mesenchymal tumours derived from the interstitial cells of Cajal. Mutations in the KIT gene leading to a constitutively activated KIT receptor protein are the m...
-
Article
Open AccessPrognosis and predictive value of KIT exon 11 deletion in GISTs
KIT exon 11 mutations are observed in 60% of gastrointestinal stromal tumours (GIST). Exon 11 codes for residues Tyr568 and Tyr570, which play a major role in signal transduction and degradation of KIT. Our aim w...
-
Article
XXVè Congrès de la SFPO « Cancers, cultures et pratiques de soins » Paris le 28 novembre 2008 Freins et motivations au dépistage des cancers du sein: quels profils typologiques ? Résultats issus de l’enquête ÉDIFICE
